hepatitis B

(redirected from Core antigen)
Also found in: Dictionary, Medical, Acronyms.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Synonyms for hepatitis B

an acute (sometimes fatal) form of viral hepatitis caused by a DNA virus that tends to persist in the blood serum and is transmitted by sexual contact or by transfusion or by ingestion of contaminated blood or other bodily fluids

Related Words

References in periodicals archive ?
Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen.
Antibody testing for HIV-1 (IgG) and total hepatitis B core antibody (IgG and IgM) was performed according to the package inserts of the Human Immunodeficiency Virus Type 1 HIV-1 EIA (Abbott 1989) and Hepatitis B Core Antigen (Recombinant) Corzyme (Abbott 1990).
Hepatitis C core antigen and its clinical applicability: potential advantages and disadvantages for diagnosis and follow-up?
Immulite 2000 anti-HBc IgM assay: IgM antibody to hepatitis B core antigen.
Alternatively, HCV core antigen testing has been utilized in some cases to monitor the efficacy of antiviral therapy.
Results from this preclinical study appear in the peer-reviewed journal, Cancer Gene Therapy, in an article entitled, "Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver.
Testing for HBsAg and hepatitis B core antigen antibody (HBc) were performed by using commercial ELISA kits (Abazyme, Needham, MA, USA, and Abnova, Taipei, Taiwan).
Hepatitis C virus protein fused to hepatitis B virus core antigen for serological diagnosis of both hepatitis C and hepatitis B infectious by ELISA.
The immunotherapy utilizes the company's proprietary spi-VEC delivery system to deliver the hepatitis B core antigen, in order to induce an immune response to the hepatitis B virus.
31, the FDA granted Pre-market Approval (PMA) to Roche for its IgM antibody to hepatitis B core antigen (Anti-HBc IgM) assay, for use on the cobas e 601 analyzer.
Food and Drug Administration (FDA) granted Premarket Approval (PMA) for its IgM antibody to hepatitis B core antigen (Anti-HBc IgM) assay for use on the cobas e 601 analyzer, the immunoassay module of the cobas 6000 analyzer series for mid-volume laboratories.
Further testing for HBeAg, anti-HBe, antibody to hepatitis B virus core antigen (anti-HBc), and immunoglobulin M to HBc would have been performed routinely to determine the need for HBIg and confirm carrier status.
For example, Copalis tests for acute or chronic hepatitis B could be configured by grouping the present HBsAg assay with an IgM antibody test to hepatitis B core antigen (anti-HBc IgM) or hepatitis B e antigen (HBsAg) and total antibody to hepatitis B core antigen (anti-HBc total) tests, respectively.
It has been shown that Hepatitis B surface (HBsAg) and core antigen (HBcAg) induces envelope-and core specific CD4+ and CD8+ T-cell responses and that the response against the Hepatitis B core antigen (HBcAg), is often associated with viral control.
The PMA submission is for use of the assay in the in-vitro qualitative determination of IgM antibodies to hepatitis B core antigen (anti-HBc IgM) in human serum or plasma.